Cholangiocarcinoma Pipeline Market - Global Outlook and Forecast 2021-2027

March 2021 | 110 pages | ID: C466266C38AEEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Cholangiocarcinoma Pipeline in Global, including the following market information:

Global Cholangiocarcinoma Pipeline Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Cholangiocarcinoma Pipeline market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cholangiocarcinoma Pipeline companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cholangiocarcinoma Pipeline Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Cholangiocarcinoma Pipeline Market Segment Percentages, By Type, 2020 (%)

• Mono
• Combination

China Cholangiocarcinoma Pipeline Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Cholangiocarcinoma Pipeline Market Segment Percentages, By Application, 2020 (%)

• Gene Therapy
• Stem Cell Therapy
• Gene Therapy

Global Cholangiocarcinoma Pipeline Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Cholangiocarcinoma Pipeline Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Cholangiocarcinoma Pipeline Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Cholangiocarcinoma Pipeline Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Medivir
• Hutchison Medipharma
• Agios Pharmaceuticals
• TransThera Biosciences
• Senhwa Biosciences
• Eisai
• EMD Serono
• Taiho Oncology
• Sirnaomics
• RedHill Biopharma
• MacroGenics
• Chia Tai Tianqing Pharmaceutical Group
• Sirtex Medical
• Delcath Systems Inc.
• Innovent Biologics
• PCI Biotech AS
• Basilea Pharmaceutica
• QED Therapeutics
• Bristol-Myers Squibb
• AstraZeneca
• Eli Lilly and Company
• Toray Industries
• Bold Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cholangiocarcinoma Pipeline Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cholangiocarcinoma Pipeline Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CHOLANGIOCARCINOMA PIPELINE OVERALL MARKET SIZE

2.1 Global Cholangiocarcinoma Pipeline Market Size: 2021 VS 2027
2.2 Global Cholangiocarcinoma Pipeline Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cholangiocarcinoma Pipeline Players in Global Market
3.2 Top Global Cholangiocarcinoma Pipeline Companies Ranked by Revenue
3.3 Global Cholangiocarcinoma Pipeline Revenue by Companies
3.4 Top 3 and Top 5 Cholangiocarcinoma Pipeline Companies in Global Market, by Revenue in 2020
3.5 Global Companies Cholangiocarcinoma Pipeline Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cholangiocarcinoma Pipeline Players in Global Market
  3.6.1 List of Global Tier 1 Cholangiocarcinoma Pipeline Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cholangiocarcinoma Pipeline Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Cholangiocarcinoma Pipeline Market Size Markets, 2021 & 2027
  4.1.2 Mono
  4.1.3 Combination
4.2 By Type - Global Cholangiocarcinoma Pipeline Revenue & Forecasts
  4.2.1 By Type - Global Cholangiocarcinoma Pipeline Revenue, 2016-2021
  4.2.2 By Type - Global Cholangiocarcinoma Pipeline Revenue, 2022-2027
  4.2.3 By Type - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cholangiocarcinoma Pipeline Market Size, 2021 & 2027
  5.1.2 Gene Therapy
  5.1.3 Stem Cell Therapy
  5.1.4 Gene Therapy
5.2 By Application - Global Cholangiocarcinoma Pipeline Revenue & Forecasts
  5.2.1 By Application - Global Cholangiocarcinoma Pipeline Revenue, 2016-2021
  5.2.2 By Application - Global Cholangiocarcinoma Pipeline Revenue, 2022-2027
  5.2.3 By Application - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Cholangiocarcinoma Pipeline Market Size, 2021 & 2027
6.2 By Region - Global Cholangiocarcinoma Pipeline Revenue & Forecasts
  6.2.1 By Region - Global Cholangiocarcinoma Pipeline Revenue, 2016-2021
  6.2.2 By Region - Global Cholangiocarcinoma Pipeline Revenue, 2022-2027
  6.2.3 By Region - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Cholangiocarcinoma Pipeline Revenue, 2016-2027
  6.3.2 US Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.3.3 Canada Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.3.4 Mexico Cholangiocarcinoma Pipeline Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Cholangiocarcinoma Pipeline Revenue, 2016-2027
  6.4.2 Germany Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.3 France Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.4 U.K. Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.5 Italy Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.6 Russia Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.7 Nordic Countries Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.4.8 Benelux Cholangiocarcinoma Pipeline Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Cholangiocarcinoma Pipeline Revenue, 2016-2027
  6.5.2 China Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.5.3 Japan Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.5.4 South Korea Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.5.5 Southeast Asia Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.5.6 India Cholangiocarcinoma Pipeline Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Cholangiocarcinoma Pipeline Revenue, 2016-2027
  6.6.2 Brazil Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.6.3 Argentina Cholangiocarcinoma Pipeline Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cholangiocarcinoma Pipeline Revenue, 2016-2027
  6.7.2 Turkey Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.7.3 Israel Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.7.4 Saudi Arabia Cholangiocarcinoma Pipeline Market Size, 2016-2027
  6.7.5 UAE Cholangiocarcinoma Pipeline Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Medivir
  7.1.1 Medivir Corporate Summary
  7.1.2 Medivir Business Overview
  7.1.3 Medivir Cholangiocarcinoma Pipeline Major Product Offerings
  7.1.4 Medivir Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.1.5 Medivir Key News
7.2 Hutchison Medipharma
  7.2.1 Hutchison Medipharma Corporate Summary
  7.2.2 Hutchison Medipharma Business Overview
  7.2.3 Hutchison Medipharma Cholangiocarcinoma Pipeline Major Product Offerings
  7.2.4 Hutchison Medipharma Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.2.5 Hutchison Medipharma Key News
7.3 Agios Pharmaceuticals
  7.3.1 Agios Pharmaceuticals Corporate Summary
  7.3.2 Agios Pharmaceuticals Business Overview
  7.3.3 Agios Pharmaceuticals Cholangiocarcinoma Pipeline Major Product Offerings
  7.3.4 Agios Pharmaceuticals Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.3.5 Agios Pharmaceuticals Key News
7.4 TransThera Biosciences
  7.4.1 TransThera Biosciences Corporate Summary
  7.4.2 TransThera Biosciences Business Overview
  7.4.3 TransThera Biosciences Cholangiocarcinoma Pipeline Major Product Offerings
  7.4.4 TransThera Biosciences Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.4.5 TransThera Biosciences Key News
7.5 Senhwa Biosciences
  7.5.1 Senhwa Biosciences Corporate Summary
  7.5.2 Senhwa Biosciences Business Overview
  7.5.3 Senhwa Biosciences Cholangiocarcinoma Pipeline Major Product Offerings
  7.5.4 Senhwa Biosciences Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.5.5 Senhwa Biosciences Key News
7.6 Eisai
  7.6.1 Eisai Corporate Summary
  7.6.2 Eisai Business Overview
  7.6.3 Eisai Cholangiocarcinoma Pipeline Major Product Offerings
  7.6.4 Eisai Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.6.5 Eisai Key News
7.7 EMD Serono
  7.7.1 EMD Serono Corporate Summary
  7.7.2 EMD Serono Business Overview
  7.7.3 EMD Serono Cholangiocarcinoma Pipeline Major Product Offerings
  7.4.4 EMD Serono Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.7.5 EMD Serono Key News
7.8 Taiho Oncology
  7.8.1 Taiho Oncology Corporate Summary
  7.8.2 Taiho Oncology Business Overview
  7.8.3 Taiho Oncology Cholangiocarcinoma Pipeline Major Product Offerings
  7.8.4 Taiho Oncology Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.8.5 Taiho Oncology Key News
7.9 Sirnaomics
  7.9.1 Sirnaomics Corporate Summary
  7.9.2 Sirnaomics Business Overview
  7.9.3 Sirnaomics Cholangiocarcinoma Pipeline Major Product Offerings
  7.9.4 Sirnaomics Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.9.5 Sirnaomics Key News
7.10 RedHill Biopharma
  7.10.1 RedHill Biopharma Corporate Summary
  7.10.2 RedHill Biopharma Business Overview
  7.10.3 RedHill Biopharma Cholangiocarcinoma Pipeline Major Product Offerings
  7.10.4 RedHill Biopharma Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.10.5 RedHill Biopharma Key News
7.11 MacroGenics
  7.11.1 MacroGenics Corporate Summary
  7.11.2 MacroGenics Business Overview
  7.11.3 MacroGenics Cholangiocarcinoma Pipeline Major Product Offerings
  7.11.4 MacroGenics Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.11.5 MacroGenics Key News
7.12 Chia Tai Tianqing Pharmaceutical Group
  7.12.1 Chia Tai Tianqing Pharmaceutical Group Corporate Summary
  7.12.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
  7.12.3 Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Major Product Offerings
  7.12.4 Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.12.5 Chia Tai Tianqing Pharmaceutical Group Key News
7.13 Sirtex Medical
  7.13.1 Sirtex Medical Corporate Summary
  7.13.2 Sirtex Medical Business Overview
  7.13.3 Sirtex Medical Cholangiocarcinoma Pipeline Major Product Offerings
  7.13.4 Sirtex Medical Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.13.5 Sirtex Medical Key News
7.14 Delcath Systems Inc.
  7.14.1 Delcath Systems Inc. Corporate Summary
  7.14.2 Delcath Systems Inc. Business Overview
  7.14.3 Delcath Systems Inc. Cholangiocarcinoma Pipeline Major Product Offerings
  7.14.4 Delcath Systems Inc. Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.14.5 Delcath Systems Inc. Key News
7.15 Innovent Biologics
  7.15.1 Innovent Biologics Corporate Summary
  7.15.2 Innovent Biologics Business Overview
  7.15.3 Innovent Biologics Cholangiocarcinoma Pipeline Major Product Offerings
  7.15.4 Innovent Biologics Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.15.5 Innovent Biologics Key News
7.16 PCI Biotech AS
  7.16.1 PCI Biotech AS Corporate Summary
  7.16.2 PCI Biotech AS Business Overview
  7.16.3 PCI Biotech AS Cholangiocarcinoma Pipeline Major Product Offerings
  7.16.4 PCI Biotech AS Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.16.5 PCI Biotech AS Key News
7.17 Basilea Pharmaceutica
  7.17.1 Basilea Pharmaceutica Corporate Summary
  7.17.2 Basilea Pharmaceutica Business Overview
  7.17.3 Basilea Pharmaceutica Cholangiocarcinoma Pipeline Major Product Offerings
  7.17.4 Basilea Pharmaceutica Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.17.5 Basilea Pharmaceutica Key News
7.18 QED Therapeutics
  7.18.1 QED Therapeutics Corporate Summary
  7.18.2 QED Therapeutics Business Overview
  7.18.3 QED Therapeutics Cholangiocarcinoma Pipeline Major Product Offerings
  7.18.4 QED Therapeutics Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.18.5 QED Therapeutics Key News
7.19 Bristol-Myers Squibb
  7.19.1 Bristol-Myers Squibb Corporate Summary
  7.19.2 Bristol-Myers Squibb Business Overview
  7.19.3 Bristol-Myers Squibb Cholangiocarcinoma Pipeline Major Product Offerings
  7.19.4 Bristol-Myers Squibb Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.19.5 Bristol-Myers Squibb Key News
7.20 AstraZeneca
  7.20.1 AstraZeneca Corporate Summary
  7.20.2 AstraZeneca Business Overview
  7.20.3 AstraZeneca Cholangiocarcinoma Pipeline Major Product Offerings
  7.20.4 AstraZeneca Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.20.5 AstraZeneca Key News
7.21 Eli Lilly and Company
  7.21.1 Eli Lilly and Company Corporate Summary
  7.21.2 Eli Lilly and Company Business Overview
  7.21.3 Eli Lilly and Company Cholangiocarcinoma Pipeline Major Product Offerings
  7.21.4 Eli Lilly and Company Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.21.5 Eli Lilly and Company Key News
7.22 Toray Industries
  7.22.1 Toray Industries Corporate Summary
  7.22.2 Toray Industries Business Overview
  7.22.3 Toray Industries Cholangiocarcinoma Pipeline Major Product Offerings
  7.22.4 Toray Industries Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.22.5 Toray Industries Key News
7.23 Bold Therapeutics
  7.23.1 Bold Therapeutics Corporate Summary
  7.23.2 Bold Therapeutics Business Overview
  7.23.3 Bold Therapeutics Cholangiocarcinoma Pipeline Major Product Offerings
  7.23.4 Bold Therapeutics Cholangiocarcinoma Pipeline Revenue in Global (2016-2021)
  7.23.5 Bold Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cholangiocarcinoma Pipeline Market Opportunities & Trends in Global Market
Table 2. Cholangiocarcinoma Pipeline Market Drivers in Global Market
Table 3. Cholangiocarcinoma Pipeline Market Restraints in Global Market
Table 4. Key Players of Cholangiocarcinoma Pipeline in Global Market
Table 5. Top Cholangiocarcinoma Pipeline Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Cholangiocarcinoma Pipeline Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Cholangiocarcinoma Pipeline Revenue Share by Companies, 2016-2021
Table 8. Global Companies Cholangiocarcinoma Pipeline Product Type
Table 9. List of Global Tier 1 Cholangiocarcinoma Pipeline Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cholangiocarcinoma Pipeline Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Cholangiocarcinoma Pipeline Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Cholangiocarcinoma Pipeline Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Cholangiocarcinoma Pipeline Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Cholangiocarcinoma Pipeline Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Cholangiocarcinoma Pipeline Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Cholangiocarcinoma Pipeline Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2022-2027
Table 30. Medivir Corporate Summary
Table 31. Medivir Cholangiocarcinoma Pipeline Product Offerings
Table 32. Medivir Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 33. Hutchison Medipharma Corporate Summary
Table 34. Hutchison Medipharma Cholangiocarcinoma Pipeline Product Offerings
Table 35. Hutchison Medipharma Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 36. Agios Pharmaceuticals Corporate Summary
Table 37. Agios Pharmaceuticals Cholangiocarcinoma Pipeline Product Offerings
Table 38. Agios Pharmaceuticals Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 39. TransThera Biosciences Corporate Summary
Table 40. TransThera Biosciences Cholangiocarcinoma Pipeline Product Offerings
Table 41. TransThera Biosciences Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 42. Senhwa Biosciences Corporate Summary
Table 43. Senhwa Biosciences Cholangiocarcinoma Pipeline Product Offerings
Table 44. Senhwa Biosciences Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 45. Eisai Corporate Summary
Table 46. Eisai Cholangiocarcinoma Pipeline Product Offerings
Table 47. Eisai Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 48. EMD Serono Corporate Summary
Table 49. EMD Serono Cholangiocarcinoma Pipeline Product Offerings
Table 50. EMD Serono Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 51. Taiho Oncology Corporate Summary
Table 52. Taiho Oncology Cholangiocarcinoma Pipeline Product Offerings
Table 53. Taiho Oncology Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 54. Sirnaomics Corporate Summary
Table 55. Sirnaomics Cholangiocarcinoma Pipeline Product Offerings
Table 56. Sirnaomics Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 57. RedHill Biopharma Corporate Summary
Table 58. RedHill Biopharma Cholangiocarcinoma Pipeline Product Offerings
Table 59. RedHill Biopharma Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 60. MacroGenics Corporate Summary
Table 61. MacroGenics Cholangiocarcinoma Pipeline Product Offerings
Table 62. MacroGenics Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 63. Chia Tai Tianqing Pharmaceutical Group Corporate Summary
Table 64. Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Product Offerings
Table 65. Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 66. Sirtex Medical Corporate Summary
Table 67. Sirtex Medical Cholangiocarcinoma Pipeline Product Offerings
Table 68. Sirtex Medical Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 69. Delcath Systems Inc. Corporate Summary
Table 70. Delcath Systems Inc. Cholangiocarcinoma Pipeline Product Offerings
Table 71. Delcath Systems Inc. Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 72. Innovent Biologics Corporate Summary
Table 73. Innovent Biologics Cholangiocarcinoma Pipeline Product Offerings
Table 74. Innovent Biologics Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 75. PCI Biotech AS Corporate Summary
Table 76. PCI Biotech AS Cholangiocarcinoma Pipeline Product Offerings
Table 77. PCI Biotech AS Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 78. Basilea Pharmaceutica Corporate Summary
Table 79. Basilea Pharmaceutica Cholangiocarcinoma Pipeline Product Offerings
Table 80. Basilea Pharmaceutica Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 81. QED Therapeutics Corporate Summary
Table 82. QED Therapeutics Cholangiocarcinoma Pipeline Product Offerings
Table 83. QED Therapeutics Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 84. Bristol-Myers Squibb Corporate Summary
Table 85. Bristol-Myers Squibb Cholangiocarcinoma Pipeline Product Offerings
Table 86. Bristol-Myers Squibb Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 87. AstraZeneca Corporate Summary
Table 88. AstraZeneca Cholangiocarcinoma Pipeline Product Offerings
Table 89. AstraZeneca Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 90. Eli Lilly and Company Corporate Summary
Table 91. Eli Lilly and Company Cholangiocarcinoma Pipeline Product Offerings
Table 92. Eli Lilly and Company Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 93. Toray Industries Corporate Summary
Table 94. Toray Industries Cholangiocarcinoma Pipeline Product Offerings
Table 95. Toray Industries Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)
Table 96. Bold Therapeutics Corporate Summary
Table 97. Bold Therapeutics Cholangiocarcinoma Pipeline Product Offerings
Table 98. Bold Therapeutics Cholangiocarcinoma Pipeline Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Cholangiocarcinoma Pipeline Segment by Type
Figure 2. Cholangiocarcinoma Pipeline Segment by Application
Figure 3. Global Cholangiocarcinoma Pipeline Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Cholangiocarcinoma Pipeline Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Cholangiocarcinoma Pipeline Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cholangiocarcinoma Pipeline Revenue in 2020
Figure 8. By Type - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 9. By Application - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 10. By Region - Global Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 11. By Country - North America Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 12. US Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 16. Germany Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 17. France Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 24. China Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 28. India Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 30. Brazil Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Cholangiocarcinoma Pipeline Revenue Market Share, 2016-2027
Figure 33. Turkey Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Cholangiocarcinoma Pipeline Revenue, (US$, Mn), 2016-2027
Figure 37. Medivir Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Hutchison Medipharma Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Agios Pharmaceuticals Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. TransThera Biosciences Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Senhwa Biosciences Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Eisai Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. EMD Serono Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Taiho Oncology Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Sirnaomics Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. RedHill Biopharma Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. MacroGenics Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Sirtex Medical Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Delcath Systems Inc. Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Innovent Biologics Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 52. PCI Biotech AS Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 53. Basilea Pharmaceutica Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 54. QED Therapeutics Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 55. Bristol-Myers Squibb Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 56. AstraZeneca Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 57. Eli Lilly and Company Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 58. Toray Industries Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 59. Bold Therapeutics Cholangiocarcinoma Pipeline Revenue Year Over Year Growth (US$, Mn) & (2016-2021)